Skip to main content

Market Overview

MiMedx: Latest Short Seller Accusation 'Unsubstantiated,' Intended To Manipulate Stock Price

MiMedx: Latest Short Seller Accusation 'Unsubstantiated,' Intended To Manipulate Stock Price

MiMedx Group Inc (NASDAQ: MDXG) shares closed down 6.6 percent Friday after Aurelius Value revived an old offensive and accused the firm of “serious and pervasive fraud” in an open letter to auditors.

Management responded to claims with counter-allegations of price manipulation.

MiMedx continues to be the target of certain unsubstantiated short seller allegations,” Robert Borchert, vice president of investor relations, said in a statement.

“We take issue when false information is maliciously spread for the purpose of manipulating our company’s stock price. We understand the balance between longs and shorts and the role each plays in our stock market, including legal short selling. However, the actions of a few can cause serious damage in the marketplace when they cross the line.”

The company has long been a short target and fought accusations from the likes of Citron Research’s Andrew Left, Viceroy Research and Marc Cohodes. In fact, over the last five months, it’s published nearly 50 pieces of commentary in response to short-selling activities.

In September, it filed a lawsuit against The Capitol for libel, slander, defamation, false light and interference with business relations.

Related Links:

Citron's New Short Thesis On MiMedx Group, Explained

Petmed Drug Removed From Google Ads After Accusations Of Fueling Opioid Crisis


Related Articles (MDXG)

View Comments and Join the Discussion!

Posted-In: Andrew Left Aurelius Research Citron Research short sellingNews Short Sellers Top Stories Exclusives Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at